Safety and Efficacy of Donor T Cells Engineered with Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK Cells) Given after T-Cell Depleted (TCD) Haploidentical Hematopoietic Transplantation (Haplo-HSCT): Results of a 14-Year Follow-Up in 45 Patients
Year: 2017
Type: article
Abstract: T-cell engineering is increasingly used in cancer immunotherapy, with long-term safety being a major issue. Since August 2002,we used TK cells after TCD haplo-HSCT to hasten immune reconstitution (IR), while controlling GvHDby suicide gene induction with ganciclovir (GCV).
Authors: Fabio Ciceri, Chiara Bonini, Myriam Labopin, Giacomo Oliveira, Arnon Nagler, Evangelia Yannaki, Maria Teresa Lupo Stanghellini, Attilio Bondanza, Raffaella Greco, Eduardo Olavarria, Eva Weissinger, Michael Stadler, Donald Bunjes, Dietger Niederwieser, Lutz Uharek, Wolfgang Bethge, John DiPersio, Andrew L. Pecora, Michele Donato, Scialini Colombi, Antonio Lambiase, Claudio Bordignon, Mohamad Mohty
Institutions: Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, IRCCS San Raffaele Roma, Hôpital Saint-Antoine, Sheba Medical Center, G. Papanikolaou General Hospital, Complejo Hospitalario de Navarra, Medizinische Hochschule Hannover, University Hospital Ulm, Leipzig University, Stiftung Charité, Charité – Universitätsmedizin Berlin, University of Tübingen, Washington University in St. Louis, Hackensack University Medical Center, MolMed (Italy)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2590623766
